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lar smooth muscle cells (SMC). Retinoids have been shown to inhibit cellu-
lar proliferation possibly due to effects on cytokines, cytokine receptors and
proto-oncogene expression.
Objective: In this study we examined whether all trans retinoic acid (RA) or
its derivatives 13-Cis RA and 9-Cis RA would prevent the 5HT induced SMC
proliferation as determined by 3[H)-thymidine incorporation into DNA.
Methods: Canine aortic primary SMC (in 2nd or 3rd passage) were in-
cubated with different concentration of RA 13-Cis RA or 9-Cis RA and
200}LM of serotonin for 20 hours in serum free medium. Then 3[H)-thymidine
(1 }LCi/plate) was added and 3[H]-thymidine incorporation into SMC was mea-
sured 4 hours later.
Results: The 200}LM of serotonin induced approximatel~ a 3-4 fold in-
crease in 3[H)-thymidine incorporation (5570 ± 242 cpm/l 0 cells to 18202
± 881 cpm/l06 cells) in SMC (n = 5). All three retinoids inhibited serotonin
induced SMC proliferation. The dose of retinoids that produced a 50% re-
duction in DNA (p < 0.00011 synthesis in SMC were 47nM for RA 410nM
for 9-Cis RA and 5}LM for 13-Cis RA. There was no evidence of cytotoxicity
with any of the retinoids to SMC up to a concentration of 1-5 mM.
Conclusion: Retinoids prevent 5HT induced SMC proliferation at low con-
centrations. Since 5HT released from platelets at sites of vascular injury may
playa role in the development of neointimal proliferation following coronary
angioplasty, retinoids may potentially be useful for prevention of restenosis
following angioplasty.
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Oxygen radicals may induce both peroxidation of polyunsaturated lipids and
protein alterations in low density lipoprotein (lDl). Oxidized lDl taken up by
macrophages via the "scavenger" receptor may contribute to formation of
foam cells. Previous studies have shown that p-blocker agents reduce exper-
imental atherosclerosis in primates. In addition, we have previously shown
that p-blocker agents inhibit oxygen radical-induced lipid peroxidation. Thus,
in this study we have investigated whether p-blockers may prevent oxidative
modifications induced by oxygen radicals on apolipoprotein-B lOO (apo-B lOO )
of lDL. Purified human lDl was exposed to oxygen radicals generated by
CuS04 (15 }LM for 20 hs at 37' C) under control conditions, or after a 30 min
pre-incubation with propranolol (P: 1-10 mM). The index of peroxidation mal-
onildihaldehyde, by thiobarbiturate method, was 2.1 ± 0.5* nmoles/mg of
protein in native lDl, 34.5 ± 4.1 in control lDL and decreased to 6.5 ± 1.8*
in lDl incubated with P (*p < 0.01 vs controls I. When oxidized lDl was run
on SDS-polyacrylamide electrophoresis (SDS-PAGE: 5 to 10% gradient) ex-
tensive apo-B lOO fragmentation was observed. Addition of P prevented the
apo-BlOO fragmentation (mean reduction from 12 to 3 bands of low molecu-
lar weight). Moreover, oxidized lDl had increased mobility on 0.8% agarose
gel electrophoresis (2.8 ± 0.4 time than controls). Similarly, incubation with
P reduced lDl mobility to 0.8 ± 0.2 fold in respect to controls (p < 0.05).
These data demostrate protection by propranonol on apo-B lOO oxidation
in vitro, at clinically relevant concentrations. Although p-blockers are known
to adversely affect lipid metabolism, inhibition of both lDl peroxidation and
apo-BlOo fragmentation may reduce uptake of oxidized lDl by macrophages
and hence foam cell formation.
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Chronic oral administration of L-arginine (l-ARG) has been shown to enhance
endothelial function in cholesterol (CHOl)-fed rabbits and to reduce athero-
genesis. We investigated whether modulation of endogenous NO produc-
tion (as assessed by urinary NO::; excretion) by l-ARG and the inhibitor of
NO synthesis, l-NAME, affects vascular superoxide (°2: 1production in hy-
percholesterolemic rabbits. Phorbol-myristate-acetate (PMA)-stimulated 02:
production from isolated aortic rings was increased in rabbits given CHOl
(+ 159 ± 28%) or CHOl + l-NAME (+ 149 ± 37%) as compared to con-
trols (-22 ± 7%), and endothelium-dependent relaxations by acetylcholine
were diminished in both groups. In aortic rings from rabbits given CHOl +
l-ARG, PMA-induced 02: production was restored to control levels (+ 14 ±
17%; p < 0.05), and endothelium-dependent cholinergic relaxations were
also partly restored. Urinary NO; excretion decreased in all animals fed a
CHOl-enriched diet (p < 0.01). As NO inactivated by 02: is also oxidized to
NO::;, this indicates a decreased endothelial production of NO. NO::; excretion
was further decreased by l-NAME (p < 0.05 vs. CHOl), and partly restored
by l-ARG (p < 0.05). We conclude that both a decreased production of NO
and an enhanced breakdown of NO by 02: contribute to the diminished bi-
ological activity of endothelial NO in hypercholesterolemia. l-ARG restores
endothelial function by enhancing NO formation and by protecting NO from
early breakdown by 02:.
3:00
1713-51 N"'-nitro-L-arginine Methyl Ester Increases Mural
Platelet Deposition and Neutrophil-endothelial
Interactions Under Low and High Shear Conditions
Patrick Provost, Jules Y.T. Lam. Montreal Heart Inst.it.ute, Montreal, Quebec, Canada
Whether infusion of a nitric oxide (NO) synthesis inhibitor, Nw-nitro-l-arginine
methyl ester (l-NAME), can modulate mural platelet deposition and neu-
trophil interaction with the endothelium underflow conditions was examined
in ex vivo bioassay experiments. Porcine aortic media, simulating deep arte-
rial wall injury, or porcine aortic endothelium was exposed to flowing arterial
blood from l-NAME-treated pigs for 5 min at 37'C under low (424 sec')
and high (3397 secl ) shear conditions in superfusion flow chambers. In-
travenous administration of l-NAME (3 mg/kg bolus + 3 mg/kg/h perfusion)
increased systolic (from 82.2 ± 2.7 to 108.5 ± 3.8 mmHg; p < 0.001). di-
astolic (from 47.4 ± 2.1 to 76.6 ± 3.6 mmHg; p < 0.001) and mean (from
59.0 ± 2.2 to 87.2 ± 3.6 mmHg; p < 0.001) arterial blood pressures with a
slight reduction in heart rate (from 155 ± 8 to 139 ± 7 beats/min: p < 0.01).
51 Cr platelet deposition on aortic media exposed to low and high shear rates
was increased, respectively, from 15.9 ± 2.9 to 20.4 ± 2.8 x 106/cm2 (p <
0.05) and from 71.4 ± 11.9 to 95.8 ± 12.5 x 106/cm2 (p < 0.02) following l-
NAME treatment. 11 'In neutrophil adhesion to intact endothelium was also
enhanced by l-NAME from 9.8 ± 2.4 to 18.3 ± 5.2 x 103/cm2 (p < 0.03)
and from 12.5 ± 4.1 to 29.1 ± 8.8 x 103/cm2 (p < 0.02) under respectively
low and high shear rates. However, platelet interaction with the endothelium
remained low and the endothelium maintained its thromboresistance.
Conclusion: Administration of the specific inhibitor of NO synthesis l-
NAME increased arterial blood pressure and enhanced platelet interaction
with the injured vessel wall and neutrophil adhesion to thromboresistant en-
dothelium under low and high shear conditions.
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To assess the role of the NO pathway in ischemic injury, the NO synthase
inhibitor l-N-Monomethylarginine (l-NMMA) was tested on isolated rab-
bit hearts retrogradely perfused with Krebs-Henseleit buffer containing 5.5
mM glucose and submitted to 30 min equilibration at 5 ml/min per g, fol-
lowed by a 60 min low-flow ischemia (10% baseline) and 30 min reperfu-
sion. Metabolic and physiological parameters of hearts treated with 1 }LM l-
NMMA added 15 min before ischemia (n = 10) were compared with similar
parameters in controls (ctrl, n = 15) without the inhibitor. Before ischemia,
l-NMMA did not influence left ventricular developed pressure or coronary
perfusion pressure but lowered cyclic GMP by 25% (P = 0.01). During is-
chemia, l-NMMA decreased the severity of ischemic contracture (25 ± 3 vs
54 ± 4 mmHg in ctrl, P < 0.001) Perfusion with D-NMMA did not protect the
heart against ischemic contracture. The effect of l-NMMA was suppressed
by 1 mM L-arginine or 10 }LM sodium nitroprussiate but not by 10 }LM 8-
Br-cyclic GMP. a cyclic GMP analogue. At the end of ischemia, exogenous
glucose uptake was 0.90 ± 0.08 and 4.0 ± 0.2 }Lmol/min per g DW (P <
0.0ll. lactate production was 4.0 ± 0.7 and 8.0 ± 0.7 }Lmollmin per g DW
(P < 0.01), glycogen was 15 ± 2 and 29 ± 5 }Lmol glucose eqJg DW (P <
0.01) and ATP was 2.5 ± 0.4 and 4.6 ± 0.3 }Lmollg DW (p < 0.01) in ctrl and
treated hearts, respectively. With reperfusion, the developed pressure was
doubled (65 ± 5 vs 32 ± 3 mmHg, P < 0.001) and the CPK release reduced
by 50% (P < 0.01) in hearts treated with l-NMMA vs ctrl. A dose-response
curve of protection against ischemic damage by l-NMMA showed that the
NO synthase inhibitor decreased ischemic contracture and enhanced glu-
cose uptake between 1 nM and 1 /LM, i.e. below concentrations inducing
vasoconstriction. It is concluded that l-NMMA protects the ischemic rab-
bit heart against cellular damage by stimulating exogenous glucose uptake,
thereby preserving endogenous energetic resources as glycogen. This pro-
tection during ischemia leads to an improvement of post-ischemic functional
recovery. This effect during ischemia seems cGMP-independent.
